Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience

作者：Li, Chao; Deng, Chengxin; Wu, Ping; Liu, Kaifan; Huang, Xin; Li, Mingmin; Chen, Xiaomei; Geng, Suxia; Lai, Peilong; Weng, Jianyu^*; Du, Xin^*

来源：CTS-Clinical and Translational Science, 2024, 17(1): e13711.

DOI：10.1111/cts.13711

• CHRONIC MYELOMONOCYTIC LEUKEMIA
• MYELODYSPLASTIC SYNDROMES
• DECITABINE
• AZACITIDINE
• NEOPLASMS
• PHASE-2
• TRIAL

Chronic myelomonocytic leukemia (CMML) treatment remains a pressing clinical challenge. We conducted a retrospective analysis on 52 CMML cases, exploring the effectiveness of combining venetoclax (Vene) with hypomethylating agents (HMAs). The study's findings show promise: the HMAs plus Vene group (n = 13, 53.8%) demonstrated superior overall response rates compared to the HMA monotherapy (mono) group (n = 19, 31.6%) and HMA plus arsenic trioxide group (n = 9, 22.2%) by the second cycle, and notably higher response rates (53.8% vs. 15.7%, p = 0.04) compared to the HMA mono group after four cycles. Over a median follow-up of 14.7 months, the HMAs plus Vene group exhibited significantly lower cumulative mortality (23.1%) compared to the other two groups (p = 0.003 and p = 0.008, respectively). Furthermore, this group displayed extended overall survival compared to the others. The study also delved into the molecular mechanisms, revealing significant BCL2 mRNA overexpression in patients with CMML. These findings suggest the potential for HMAs combined with Vene therapy in CMML but emphasize the necessity for further prospective studies to determine its precise role in managing CMML.

• 单位
  广东省人民医院; 南方医科大学